PEG-rhG-CSF预防肺癌患者化疗后粒细胞减少症的疗效观察OA

Objective To investigate the clinical efficacy of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in preventing granulocytopenia in lung cancer patients after chemotherapy.Methods Lung cancer patients who were recommended for prophylactic administration according to the risk stratification of granulocytopenia with fever from October 2023 to September 2024 were selected and divided into observation group(n=40,treated with PEG-rhG-CSF)and control group(n=40,treated with rhG-CSF).Both groups were given platinum-based doublet chemotherapy regimen.The incidence of myelosuppression and granulocytopenia,blood routine parameters[red blood cell count(RBC),white blood cell count(WBC),hemoglobin(Hb),neutrophil count(NEU),platelet count(PLT)],changes in Karnofsky performance status(KPS)score and adverse reactions were compared between the two groups.Results The incidence of grade Ⅲ-Ⅳmyelosuppression in the observation group was 15.00%(6/40),which was lower than 35.00%(14/40)in the control group(P<0.05).The incidence of grade Ⅲ granulocytopenia and the overall incidence of granulocytopenia in the observation group were lower than those in the control group,and the recovery time for absolute neutrophil count was shorter than that in the control group(P<0.05).At 7 and 14 d after treatment,WBC,NEU,Hb,RBC and PLT in the observation group were higher than those in the control group(P<0.05).The total effective rate of KPS score in the observation group was 77.50%(31/40),which was higher than 55.00%(22/40)in the control group(P<0.05).The incidence of injection site pain/bone pain in the observation group was 5.00%(2/40),which was lower than 20.00%(8/40)in the control group(P<0.05).Conclusion PEG-rhG-CSF can better prevent chemotherapy-induced granulocytopenia in patients with lung cancer,improve the quality of life of patients,and reduce the incidence of injection site pain/bone pain.